title: Human papillomavirus vaccines in development: if they're successful in clinical trials, how will they be implemented?
abstract: BACKGROUND
  There are some 30-40 genotypes of human papillomavirus (HPV) that cause anogenital lesions in humans, primarily cervical, vaginal, and vulvar dysplasias and cancer in women, anal dysplasias in some men, and genital warts in both sexes.
  
  
  METHODS
  Both GlaxoSmithKline and Merck companies are developing vaccines for the prevention of HPV infection.
  
  
  RESULTS
  Both vaccines stimulate an antibody response against HPV types 16 and 18; the Merck vaccine also include HPV types 6 and 11.
  
  
  CONCLUSIONS
  This report focuses on progress with both prophylactic vaccines and introduces strategies for global immunization.
authors.affiliation: Merck Vaccine Division, West Point, PA 19486, USA.
authors.forename: Alan R
authors.initials: AR
authors.lastname: Shaw
mesh_terms: D002986:Clinical Trials as Topic; D006801:Humans; D027383:Papillomaviridae / Q000276:immunology*; D030361:Papillomavirus Infections / Q000517:prevention & control*; D053918:Papillomavirus Vaccines; D014611:Vaccination / Q000379:methods; D014765:Viral Vaccines / Q000737:chemistry / Q000276:immunology / Q000627:therapeutic use*
chemical_list: D053918:Papillomavirus Vaccines; D014765:Viral Vaccines